ENHANCE Study - Optimization of intra-tumour illumination and changes in patient population NewsadminMarch 5, 2013
PCI Biotech – Winner of both DnB NOR’s Innovation prize 2011 and the People’s award NewsadminSeptember 7, 2011
Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells. NewsadminMarch 16, 2010
PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex® trial. Strong anti-tumour response observed in all patients NewsadminJanuary 19, 2010
Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Cancer NewsadminDecember 3, 2009
Successful completion of the first dose group in the Phase I/II study of Amphinex® in cancer patients NewsadminOctober 19, 2009
First cancer patient included in PCI Biotech's Phase I/II trial of Amphinex® NewsadminAugust 24, 2009
PCI Biotech-led consortium awarded EUR 1.1 million grant from the EU Eurostars Programme NewsadminMarch 23, 2009
